Maternal vaccines act as a guiding force in public health by serving to prevent dangerous and pervasive infectious diseases clustered in the neonatal period through transplacental transfer of IgG antibodies. Specifically, immunization in pregnancy is shown to reduce neonatal mortality and illnesses such as influenza, pertussis, and tetanus. As the scientific community continues to weigh maternal vaccines as a key strategy to reduce infant mortality and severe illness, barriers and facilitators to vaccine acceptance must be evaluated to support the vaccine ecosystem and improve vaccine policy and program implementation. Mothers’ knowledge, attitudes, and beliefs towards maternal vaccines play an important role in determining vaccine acceptance, and should be considered when evaluating the underlying mechanisms to vaccine uptake.

The scope of the problem

It is estimated that 46% of all deaths in children under five occur during the neonatal period with a large proportion of those deaths due to sepsis, prematurity, pneumonia and tetanus. While this is most likely an underestimate due to knowledge gaps in the global burden of disease, specifically in low and middle-income countries (LMICs), this data reveals the need for new and/or improved interventions to protect children during this critical period. A call to action within the scientific community to address these statistics, laid forth by the UN Sustainable Development Goals, has led to the development of new vaccines, particularly maternal vaccines.

Vaccination of pregnant women is widely recommended against a host of pathogens for mother and infant by preventing the disease in mothers and preventing transmission of the disease to infants through protective maternal antibodies. Currently, the World Health Organization (WHO) recommends three maternal immunization strategies: (1) influenza vaccine, which GAVI estimates could prevent 45 deaths per 100,000 people vaccinated, (2) maternal tetanus vaccine, which has reduced neonatal tetanus by an estimated 94% (95% CI: 80–98), and (3) the Tdap vaccine, which is recommended on a limited basis and is thought to be the most cost-effective strategy for reducing neonatal and infant pertussis. Specifically, the Strategic Advisory Group of Experts on Immunization (SAGE) recommends vaccination against tetanus during pregnancy and identifies pregnant women as a priority group for influenza vaccination in countries that administer or plan to introduce the vaccine. There are also candidate maternal vaccines being developed for respiratory syncytial virus (RSV) and group B streptococcus, that are estimated to be major causes of neonatal morbidity and mortality worldwide, and may also share the same association between maternal antibody and infant protection as influenza, pertussis, and tetanus.

Currently, the main driver behind a new vaccine introduction or inclusion in a country’s National Immunization Program (NIP) is disease burden. While global burden of disease models produce best-estimates, the paucity of local data in LMICs expressing the burden of disease prevents
Ministries of Health from analyzing context-specific implications for the introduction of new vaccines. Maternal vaccines hold great promise to reduce infant deaths, but a lack of burden of disease estimates across global contexts limits our ability to understand the potential impact a vaccine program might have on reducing infant mortality.\textsuperscript{11}

Equally important to vaccine introduction is exploring potential challenges to implementation from both a policy and programmatic perspective, particularly when considering the financial investment in pipeline vaccines and the potential they hold to reduce neonatal mortality. As the scientific community continues to deepen its understanding of the true potential impact of maternal vaccines, vaccine hesitancy is increasingly posing a challenge to vaccine uptake.\textsuperscript{12} Vaccine hesitancy, or the decision to delay or refuse vaccination, impacts both immunization rates and the ability of a vaccine to reach its full potential, which is why it must be considered a significant challenge to reducing global vaccine-preventable neonatal morbidity and mortality.

**Known drivers to vaccine uptake**

From the policy perspective, both global and national governing bodies must approve the implementation of a vaccine before it is introduced into the country’s NIP. First, SAGE completes an analysis of the vaccine and determines whether there should be a global recommendation. A global recommendation is then considered by the national Ministry of Health, where the National Immunization Technical Advisory Group (NITAG) completes a country-specific analysis similar to that of SAGE, followed by the regulatory approvals and procurement phase. Ultimately, the determining factor in the development of vaccine policy is approval from the national Ministry of Health.

Once the policy has been established, successful implementation of a new vaccine can be influenced by several factors. The most frequently studied factors that facilitate or inhibit vaccine utilization globally are structural barriers such as cost, availability, and accessibility of vaccines. These barriers are to a large extent already known and are considered by vaccine policy and program implementers. In addition to these factors, the vaccine community must also consider vaccine hesitancy. An increasingly common phenomenon, vaccine hesitancy poses a threat to infectious disease reduction worldwide.\textsuperscript{12} Vaccine hesitancy has been a research focus at WHO with contributions from various stakeholders including both governments and the private sector: they have developed tools to access vaccine confidence and utilization among pregnant women, which can aid in the development of interventions to target vaccine hesitancy across global contexts.\textsuperscript{11,13}

Maternal knowledge of vaccines, coupled with attitudes and beliefs, contribute to or alay vaccine hesitancy.\textsuperscript{14} In fact, several studies looking at barriers and facilitators to the maternal influenza vaccine demonstrate that knowledge was a key determining factor in vaccine uptake.\textsuperscript{15–17} Other research has shown that there is a relationship between maternal vaccine hesitancy, intention to vaccinate, and maternal and child vaccine rates.\textsuperscript{18} Maternal knowledge, attitudes, and beliefs therefore should be considered not only by policy implementers and researchers alike, but prioritized as a key potential barrier when considering current and future maternal immunizations.

**Considering maternal vaccine knowledge, attitudes, and beliefs**

The existence of safe and effective maternal vaccines will only prove useful if mothers decide to use them. Maternal knowledge, attitudes, and beliefs around vaccines are an integral part of the underlying mechanisms of vaccine hesitancy. Understanding these factors will allow public health practitioners to design more effective interventions.

While research on vaccine hesitancy and the factors that determine uptake is burgeoning in developing countries where the phenomenon is known to be most studied and increasingly prevalent, very little is known about maternal knowledge, attitudes, and beliefs toward maternal vaccines in resource-limited settings.\textsuperscript{19,20} A recent study in Zambia revealed that mothers had a limited knowledge of vaccines, but expressed positive views about vaccinating themselves and their children. Mitigating beliefs and norms such as paternal involvement and community rumors influenced women’s attitudes toward vaccination.\textsuperscript{21} Further research in Zambia explored vaccine attitudes and hesitancy and found that lack of knowledge, along with other factors such as traditional religious practices, created misgivings toward western medicine amongst some participants.\textsuperscript{22} In other studies conducted in low-resource settings, researchers found that acceptability of maternal tetanus toxoid (Ivory Coast) and maternal Tdap vaccine (Pakistan) was good, but similarly noted that the mother’s partner’s opinions strongly affected women’s attitudes and actions toward vaccinations; the study also noted that immunization campaigns should be directed toward men, as well as mothers.\textsuperscript{23,24} Additionally, research conducted in Saudi Arabia revealed that about a quarter of women surveyed were unwilling to get the maternal influenza vaccine, and that women with limited knowledge of vaccinations were significantly less likely to get vaccinated than those with greater knowledge of vaccinations.\textsuperscript{25} Similarly, research in Mexico demonstrated that knowledge of pertussis vaccination was independently associated with the intention to receive maternal Tdap amongst pregnant women.\textsuperscript{26} As demonstrated, studies of maternal vaccine knowledge, attitudes and beliefs have been sporadically conducted in LMICs, and as such the data is not sufficient to glean insights on whether these factors contribute to vaccine hesitancy at the global level.

Research exploring maternal attitudes toward childhood vaccines has also shown to be associated with uptake. The majority of research on this topic found that mothers’ knowledge of immunizations was a factor associated with the decision to vaccinate their children.\textsuperscript{27–29} Attitudes also played a significant factor; in one three-country study of maternal vaccine acceptance, maternal attitudes toward the government and trust in the healthcare system was shown to influence vaccine uptake.\textsuperscript{30} The parallels between a mother choosing to vaccinate her child versus choosing to vaccinate her child in
Maternal vaccines contain great potential to reduce the global burden of infant morbidity and mortality, with their unique position to access the infant’s immune system through maternal antibodies before a child vaccine could be effective. However, vaccine hesitancy, driven largely by maternal knowledge of vaccines, threatens to curtail the potential successes of such vaccines, thereby hindering public health goals to reduce the global burden of neonatal infectious disease and mortality. Across both policy and programmatic levels, addressing barriers to vaccine uptake, such as maternal knowledge, attitudes, and beliefs of maternal vaccines, is paramount to effective implementation and ultimate disease reduction.

Disclosure of potential conflicts of interest
The authors have no competing financial interests. During manuscript development, Rachel Mitrovich received monies from Merck & Co., Inc. for consultancy services with no influence on the work involved in this publication.

References
1. Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Fry NK, Ramsay M. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. Clin Infect Dis. 2015;60(3):333–337. doi:10.1093/cid/ciu821.
2. Blencowe H, Lawn J, Vanderlaar J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol. 2010;39(Supplement 1):102–109. doi:10.1093/ije/dyp027.

3. World Health Organization. Vaccines against influenza: WHO position paper. Wkly Epidemiol Rec. 2012, http://www.who.int/immunization/policy/position_papers/influenza/en/.

4. WHO | Causes of child mortality. WHO. 2018 accessed 2018 Aug 21. http://www.who.int/gho/child_health/mortality/causes/en/.

5. Marshall H, McMillan M, Andrews RM, Macartney K, Edwards K. Vaccines in pregnancy: the dual benefit for pregnant women and infants. Hum Vaccin Immunother. 2016;12(4):848–856. doi:10.1080/21645515.2015.1127485.

6. World Health Organization. Pertussis vaccines: WHO position paper—August 2015. Wkly Epidemiol Rec. 2015;90(35):433–460. http://www.who.int/wer/2015/wer9035.pdf?ua=1.

7. Organization WH. Tetanus vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(6):53–76. http://apps.who.int/iris/bitstream/10665/254821/1/WER9206.pdf?ua=1.

8. Alliance G Influenza Vaccine Investment Strategy. https://www.gavi.org/library/gavi-documents/strategy/final-vis-analysis-2013-maternal-influenza/.

9. Heath PT, Culley FJ, Jones CE, Kampmann B, Le Doare K, Nunes MC, Sadrangani M, Chaudhry Z, Baker CJ, Oppenheimer PM. Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infect Dis. 2017;17(7):e223–e234. doi:10.1016/S1473-3099(17)30232-3.

10. Chen VL, Avci FY, Kasper DL. A maternal vaccine against group B Streptococcus: past, present, and future. Vaccine. 2013;31(Suppl 4):D13–9. doi:10.1016/j.vaccine.2012.12.080.

11. Lambach P, Hombach J, Ortiz JR. A global perspective of maternal influenza immunization. Vaccine. 2015;33(47):6376–6379. doi:10.1016/j.vaccine.2015.08.036.

12. Lane S, MacDonald NE, Marti M, Dumolard L. Vaccine hesitancy around the globe: analysis of three years of WHO/UNICEF joint reporting form data-2015–2017. Vaccine. 2018;36(26):3861–3867. doi:10.1016/j.vaccine.2018.03.063.

13. World Health Organization. Tailoring Immunization Programmes for Seasonal Influenza. 2015. Copenhagen Publisher: World Health Organization Regional Office for Europe.

14. SAGE Working Group W. Report of the SAGE Working Group on Vaccine Hesitancy. 2014. http://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf

15. Bushar JA, Kendrick JS, Ding H, Black CL, Greby SM. Text4baby influenza messaging and influenza vaccination among pregnant women. Am J Prev Med. 2017;53(6):845–853. doi:10.1016/j.amepre.2017.06.021.

16. Eppes C, Wu A, You W, Cameron KA, Garcia P, Grobman W. Barriers to influenza vaccination among pregnant women. Vaccine. 2013;31(27):2874–2878. doi:10.1016/j.vaccine.2013.04.031.

17. Yuen CYS, Tarrant M. Determinants of uptake of influenza vaccination among pregnant women – A systematic review. Vaccine. 2014;32(36):4602–4613. doi:10.1016/j.vaccine.2014.06.067.

18. Danchin MH, Costa-Pinto J, Attwell K, Willaby H, Wiley K, Hoq M, Leask J, Perrett KP, O’Keefe J, Giles ML, et al. Vaccine decision-making begins in pregnancy: correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake. Vaccine. 2017 Aug. doi:10.1016/j.vaccine.2017.08.003.

19. Donaldson B, Jain P, Holder BS, Lindsey B, Regan L, Kampmann B. What determines uptake of pertussis vaccine in pregnancy? A cross sectional survey in an ethnically diverse population of pregnant women in London. Vaccine. 2015;33(43):5822–5828. doi:10.1016/j.vaccine.2015.08.093.

20. Maher L, Dawson A, Wiley K, Hope K, Torvaldsen S, Lawrence G, Conaty S. Influenza vaccination during pregnancy: a qualitative study of the knowledge, attitudes, beliefs, and practices of general practitioners in Central and South-Western Sydney. BMC Fam Pract. 2014;15(1):102. doi:10.1186/1471-2296-15-102.

21. Larson Williams A, McCloskey L, Mwale M, Mwananyanda L, Murray K, Herman AR, Thea DM, MacLeod WB, Gill CJ. "When you are injected, the baby is protected." Assessing the acceptability of a maternal Tdap vaccine based on mothers’ knowledge, attitudes, and beliefs of pertussis and vaccinations in Lusaka, Zambia. Vaccine. 2018;36(21):3048–3053. doi:10.1016/j.vaccine.2018.03.081.

22. Pugliese-Garcia M, Heyerdahl LW, Mwamba C, Nkwemuzi S, Chilengi R, Demolis R, Guillermet E, Sharma A. Factors influencing vaccine acceptance and hesitancy in three informal settlements in Lusaka, Zambia. Vaccine. 2018;36(5):5617–5624. doi:10.1016/j.vaccine.2018.07.042.

23. Ymba A, Perrey C. Acceptability of tetanus toxoid vaccine by pregnant women in two health centres in Abidjan (Ivory Coast). Vaccine. 2003;21(24):3497–3500. accessed 2018 Aug 20. http://www.ncbi.nlm.nih.gov/pubmed/12850368.

24. Siddiqui M, Khan AA, Varan AK, Esteses-Jaramillo A, Sultana S, Ali AS, Zaidi AKM, Omer SB. Intention to accept pertussis vaccine among pregnant women in Karachi, Pakistan. Vaccine. 2017;35(40):5352–5359. doi:10.1016/j.vaccine.2017.08.033.

25. Mayet AY, Al-Shaikh GK, Al-Mandeel HM, Alsaleh NA, Hamad AF. Knowledge, attitudes, beliefs, and barriers associated with the uptake of influenza vaccine among pregnant women. Saudi Pharm J. 2017;25(1):76–82. doi:10.1016/j.jspsj.2015.12.001.

26. Varan AK, Esteses-Jaramillo A, Richardson V, Esparza-Aguilar M, Cervantes-Powell P, Omer SB. Intention to accept Bordetella pertussis booster vaccine during pregnancy in Mexico City. Vaccine. 2014;32(7):785–792. doi:10.1016/j.vaccine.2013.12.054.

27. Hu Y, Chen Y, Wang Y, Song Q, Li Q. Prenatal vaccination education intervention improves both the mothers’ knowledge and children’s vaccination coverage: evidence from randomized controlled trial from eastern China. Hum Vaccin Immunother. 2017;13(6):1477–1484. doi:10.1080/21645515.2017.1285476.

28. Legesse E, Dechasa W. An assessment of child immunization coverage and its determinants in Sinana District, Southeast Ethiopia. BMC Pediatr. 2015;15(1):31. doi:10.1186/s12887-015-0345-4.

29. Adefiere EB, Ajayi I, Fawole OI, Ajumobi O, Kasasa S, Wasssa P, Nguku P. Immunisation coverage and its determinants among children aged 12-23 months in Atakumosa-west district, Osun State Nigeria: a cross-sectional study. BMC Public Health. 2016;16(1):905. doi:10.1186/s12889-016-3531-x.

30. Handy LK, Maroudi S, Powell M, Nila B, Moser C, Japa I, Monyatsi N, Tzortzi E, Kouzeli I, Luberti A, et al. The impact of access to immunization information on vaccine acceptance in three countries. Newman PA, ed. PLoS One. 2017;12(8):e0180759. doi:10.1371/journal.pone.0180759.

31. MacDonald NE, Butler R, Dubé E. Addressing barriers to vaccine acceptance: an overview. Hum Vaccin Immunother. 2018;14(1):218–224. doi:10.1080/21645515.2017.1394533.